Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFevertree Regulatory News (FEVR)

Share Price Information for Fevertree (FEVR)

Share Price is delayed by 15 minutes
Get Live Data
825.50    0.00 (0.00%)
Bid:
0.00
Ask:
900.00
Spread: 77.00 (9.356%)
Market Cap: £938.33m
FEVR Live PriceLast checked at - London Stock Exchange

Intraday Fevertree Share Chart

Commencement of share buyback programme

17 Feb 2025 07:00

RNS Number : 2209X
Fevertree Drinks PLC
17 February 2025
 

17 February 2025

Fevertree Drinks plc

("Fever-Tree" or the "Company")

 

Commencement of share buyback programme

Fever-Tree today announces the commencement of a share buyback programme regarding the purchase of ordinary shares in the Company with a nominal value of 0.25 pence each (the "Shares") up to a maximum consideration of £71 million (the "Programme").

Fever-Tree previously announced its intention to commence the Programme on 30 January 2025, alongside the announcement its strategic partnership with Molson Coors for the exclusive sales, distribution and production of the Fever-Tree brand in the US.

Fever-Tree has entered into a non-discretionary agreement with Investec Bank plc ("Investec") to purchase Shares on its behalf and to make trading decisions independently of the Company. The Programme will commence today, 17 February 2025, and end no later than 30 September 2025. The sole purpose of the Programme is to reduce the share capital of Fever-Tree. As such, the Company intends to cancel any Shares purchased.

Investec will purchase the Shares as principal and simultaneously be deemed to execute sales to the Company of any Shares so purchased in accordance with the terms of their engagement.

Any purchase of Shares under the Programme will be executed in accordance with certain pre-set parameters and in accordance with the Company's existing general authority to repurchase Shares granted by its shareholders at the annual general meeting held on 6 June 2024 (which permits the Company to purchase no more than 11,668,664 Shares), the Market Abuse Regulation (596/2014) as it forms part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as amended) and UKLR 9.6.2 using the average daily volume of Ordinary Shares traded in January 2025, being the month preceding the month of this announcement. The Company may repurchase up to 25% of this average daily volume per day during the programme.

 

For further information:

 

Fever-Tree

Investor queries

Ann Morris-Gibbons, Director of Investor Relations I ann.hyams@fever-tree.com I +44 (0)7435 828 138

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

 

Nominated Advisor and Broker - Investec Bank plc

David Flin I +44 (0)20 7597 5970

Financial Adviser & Corporate Broker - Morgan Stanley & Co. International plc

Henry Stewart I Andrew Foster I Jessica Pauley I +44 (0)20 7425 8000

Corporate Broker - Jefferies International Limited

Ed Matthews I Richard Taylor I +44 (0)20 7029 8000

Financial PR advisers - FGS Global

Faeth Birch +44 (0)7768 943 171; Anjali Unnikrishnan +44 (0) 7826 534 233

About Fever-Tree:

Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to over 90 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On Trade") as well as selected retail outlets ("Off Trade").

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAAALFFNSEFA
Date   Source Headline
23rd Jun 20267:00 amRNSTransaction in Own Shares
16th Jun 20267:00 amRNSTransaction in Own Shares
9th Jun 202612:46 pmRNSResults of AGM
9th Jun 20267:00 amRNSAGM Trading Statement
9th Jun 20267:00 amRNSTransaction in Own Shares
2nd Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20269:35 amRNSTotal Voting Rights
27th May 20267:00 amRNSTransaction in Own Shares
22nd May 20269:51 amRNSHolding(s) in Company
19th May 20267:00 amRNSTransaction in Own Shares
12th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSTransaction in Own Shares
1st May 20267:00 amRNSTotal Voting Rights
28th Apr 20264:00 pmRNSGrant of Options
28th Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20265:35 pmRNSDividend Timetable Update
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20265:11 pmRNS2025 Annual Report and Notice of AGM
14th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSTransaction in Own Shares
1st Apr 202611:02 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSFY25 Preliminary Results to 31 December 2025
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20262:47 pmRNSTotal Voting Rights
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.